{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:59:44Z","timestamp":1772762384128,"version":"3.50.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":721,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970698"],"award-info":[{"award-number":["81970698"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7202216"],"award-info":[{"award-number":["7202216"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970698"],"award-info":[{"award-number":["81970698"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7202216"],"award-info":[{"award-number":["7202216"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Whether sodium-glucose co-transporter 2 inhibitors are effective for heart failure caused by ATTR-CA (transthyretin cardiac amyloidosis) remains uncertain. The aim of this study is to investigate the cardiovascular prognosis in ATTR-CA mice model with dapagliflozin treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Humanized RBP4\/TTRVal50Met and RBP4\/TTR mice models were constructed with clustered regularly interspaced short palindromic repeats and associated Cas9 endonuclease (CRISPR-Cas9) techniques and multiple generations breeding. A total of 6 RBP4\/TTR mice received placebo treatment, when 12 RBP4\/TTRVal50Met received dapagliflozin (1 mg\/kg\/day, 6 mice) and placebo (6 mice) treatment. Fasting glucose, intraperitoneal glucose tolerance test, and plasma brain natriuretic peptide (BNP) concentration were measured at Day 0, Week 2, and Week 4. BNP, transforming growth factor-beta (TGF-\u03b2), collagen type I alpha 1 (COL1A1) protein levels, and Cola1, TGF\u03b21, TNF\u03b1, IL-1\u03b2, BNP relative quantities in cardiac, along with cardiac pathology examination including right ventricular collagen percentage, ventricular septum thickness, left ventricular wall thickness, and left ventricular internal diameter were measured at Week 4 after treatment procedure. All 18 mice completed the experiment. The baseline characteristics were balanced among three treatment groups. In placebo-treated mice, the cardiac BNP relative quantity was significantly higher in RBP4\/TTRVal50Met mice than RBP4\/TTR mice (RBP4[KI\/KI], TTR [KI\/KI]: 0.72 \u00b1 0.46, RBP4[KI\/KI], TTRVal50Met[KI\/KI]: 1.44 \u00b1 0.60, P = 0.043), indicating more significant heart failure progression in ATTR-CA mice than normal mice. In ATTR-CA mice, the cardiovascular prognosis measurements including heart failure (plasma BNP concentration and relative quantities of BNP), cardiac inflammation (relative quantities of Cola1, TGF\u03b21, TNF\u03b1, and IL-1\u03b2), and pathological changes (right ventricular collagen percentage, ventricular septum thickness, left ventricular wall thickness, and left ventricular internal diameter) were statistically comparable between those under dapagliflozin and placebo treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Dapagliflozin did not improve cardiovascular prognosis including the progression of heart failure, cardiac inflammation, and pathological changes in ATTR-CA mice compared with placebo. The results of this study were not in support of dapagliflozin's therapeutic effects for ATTR-CA. More pre-clinical and clinical researches to validate these findings and demonstrate the underlying mechanisms are still required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14567","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T05:59:56Z","timestamp":1698213596000},"page":"179-188","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Dapagliflozin Treatment and Cardiovascular Outcome in RBP4\/TTRVal30Met (Transthyretin Cardiac Amyloidosis) Mice"],"prefix":"10.1093","volume":"11","author":[{"given":"Zonglin","family":"Li","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking University People's Hospital , No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking University People's Hospital , No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking University People's Hospital , No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengcheng","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking University People's Hospital , No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking University People's Hospital , No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7881-0543","authenticated-orcid":false,"given":"Xiaoling","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking University People's Hospital , No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chu","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking University People's Hospital , No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengqing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking University People's Hospital , No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjia","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking University People's Hospital , No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linong","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking University People's Hospital , No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,10,25]]},"reference":[{"key":"2026012113073201900_ehf214567-bib-0001","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101487","article-title":"Therapy of ATTR cardiac amyloidosis: Current indications","volume":"48","author":"Di Lisi","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"2026012113073201900_ehf214567-bib-0002","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/ehf2.12518","article-title":"Transthyretin cardiac amyloidosis: An update on diagnosis and treatment","volume":"6","author":"Yamamoto","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2026012113073201900_ehf214567-bib-0003","doi-asserted-by":"publisher","first-page":"17","DOI":"10.14797\/mdcvj.1066","article-title":"ATTR epidemiology, genetics, and prognostic factors","volume":"18","author":"Obi","year":"2022","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"2026012113073201900_ehf214567-bib-0004","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonzalez-Lopez","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012113073201900_ehf214567-bib-0005","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40120-020-00210-7","article-title":"Transthyretin amyloidosis: Update on the clinical spectrum, pathogenesis, and disease-modifying therapies","volume":"9","author":"Koike","year":"2020","journal-title":"Neurol Ther"},{"key":"2026012113073201900_ehf214567-bib-0006","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.jaccao.2021.06.006","article-title":"ATTR amyloidosis: Current and emerging management strategies: JACC: CardioOncology state-of-the-art review","volume":"3","author":"Griffin","year":"2021","journal-title":"JACC CardioOncol"},{"key":"2026012113073201900_ehf214567-bib-0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2022.105313","article-title":"Transthyretin: Its function and amyloid formation","volume":"155","author":"Ueda","year":"2022","journal-title":"Neurochem Int"},{"key":"2026012113073201900_ehf214567-bib-0008","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1515\/bmc-2013-0038","article-title":"Transthyretin: A multifaceted protein","volume":"5","author":"Vieira","year":"2014","journal-title":"Biomol Concepts"},{"key":"2026012113073201900_ehf214567-bib-0009","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejim.2020.09.025","article-title":"Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery","volume":"82","author":"Porcari","year":"2020","journal-title":"Eur J Intern Med"},{"key":"2026012113073201900_ehf214567-bib-0010","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1002\/ehf2.13541","article-title":"Natural history and progression of transthyretin amyloid cardiomyopathy: Insights from ATTR-ACT","volume":"8","author":"Nativi-Nicolau","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012113073201900_ehf214567-bib-0011","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/FJC.0000000000001004","article-title":"A review of novel agents and clinical considerations in patients with ATTR cardiac amyloidosis","volume":"77","author":"Benbrahim","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026012113073201900_ehf214567-bib-0012","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-001007","article-title":"Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes","volume":"2","author":"Clar","year":"2012","journal-title":"BMJ Open"},{"key":"2026012113073201900_ehf214567-bib-0013","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2026012113073201900_ehf214567-bib-0014","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00125-017-4390-4","article-title":"Diabetic cardiomyopathy: A hyperglycaemia- and insulin-resistance-induced heart disease","volume":"61","author":"Jia","year":"2018","journal-title":"Diabetologia"},{"key":"2026012113073201900_ehf214567-bib-0015","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/1440-1681.12725","article-title":"Effect of a selective SGLT2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats","volume":"44","author":"Rahman","year":"2017","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2026012113073201900_ehf214567-bib-0016","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012113073201900_ehf214567-bib-0017","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ehf2.14188","article-title":"SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: Early tolerance and clinical response to dapagliflozin","volume":"10","author":"Dobner","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026012113073201900_ehf214567-bib-0018","volume-title":"Guide for the Care and Use of Laboratory Animals","author":"National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals","year":"2011","edition":"8"},{"key":"2026012113073201900_ehf214567-bib-0019","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41374-017-0019-y","article-title":"Amyloid deposition in a mouse model humanized at the transthyretin and retinol-binding protein 4 loci","volume":"98","author":"Li","year":"2018","journal-title":"Lab Invest"},{"key":"2026012113073201900_ehf214567-bib-0020","doi-asserted-by":"publisher","first-page":"S107","DOI":"10.1002\/msj.21352","article-title":"Hereditary ATTR amyloidosis: Burden of illness and diagnostic challenges","volume":"23","author":"Gertz","year":"2017","journal-title":"Am J Manag Care"},{"key":"2026012113073201900_ehf214567-bib-0021","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/0002-9343(83)90443-6","article-title":"Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation","volume":"75","author":"Cornwell","year":"1983","journal-title":"Am J Med"},{"key":"2026012113073201900_ehf214567-bib-0022","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation"},{"key":"2026012113073201900_ehf214567-bib-0023","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","article-title":"Transthyretin (ATTR) amyloidosis: Clinical spectrum, molecular pathogenesis and disease-modifying treatments","volume":"86","author":"Sekijima","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026012113073201900_ehf214567-bib-0024","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: Disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"key":"2026012113073201900_ehf214567-bib-0025","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1016\/j.jcmg.2019.06.023","article-title":"Myocardial amyloidosis: The exemplar interstitial disease","volume":"12","author":"Fontana","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012113073201900_ehf214567-bib-0026","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1093\/eurheartj\/ehz298","article-title":"Treatment of cardiac transthyretin amyloidosis: An update","volume":"40","author":"Emdin","year":"2019","journal-title":"Eur Heart J"},{"key":"2026012113073201900_ehf214567-bib-0027","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.mayocp.2021.08.006","article-title":"Beta-blocker exposure and survival in patients with transthyretin amyloid cardiomyopathy","volume":"97","author":"Barge-Caballero","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"2026012113073201900_ehf214567-bib-0028","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1378\/chest.104.2.618","article-title":"Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis","volume":"104","author":"Pollak","year":"1993","journal-title":"Chest"},{"key":"2026012113073201900_ehf214567-bib-0029","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.12688\/f1000research.20447.1","article-title":"Recent advances in the treatment of chronic heart failure","volume":"8","author":"Buckley","year":"2019","journal-title":"F1000Res"},{"key":"2026012113073201900_ehf214567-bib-0030","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.752370","article-title":"Potential mechanisms of SGLT2 inhibitors for the treatment of heart failure with preserved ejection fraction","volume":"12","author":"Pabel","year":"2021","journal-title":"Front Physiol"},{"key":"2026012113073201900_ehf214567-bib-0031","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10557-018-6837-3","article-title":"Dapagliflozin attenuates Na+\/H+ exchanger-1 in cardiofibroblasts via AMPK activation","volume":"32","author":"Ye","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026012113073201900_ehf214567-bib-0032","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1042\/CS20190585","article-title":"Empagliflozin prevents cardiomyopathy via sGC-cGMP-PKG pathway in type 2 diabetes mice","volume":"133","author":"Xue","year":"2019","journal-title":"Clin Sci (Lond)"},{"key":"2026012113073201900_ehf214567-bib-0033","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1093\/cvr\/cvaa256","article-title":"The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction","volume":"117","author":"Withaar","year":"2021","journal-title":"Cardiovasc Res"},{"key":"2026012113073201900_ehf214567-bib-0034","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1161\/CIRCULATIONAHA.121.056824","article-title":"Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-Preserved trial","volume":"144","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"2026012113073201900_ehf214567-bib-0035","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: A multicenter randomized trial","volume":"27","author":"Nassif","year":"2021","journal-title":"Nat Med"},{"key":"2026012113073201900_ehf214567-bib-0036","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.5604\/17322693.1226695","article-title":"Retinol-binding protein 4 (RBP4) as the causative factor and marker of vascular injury related to insulin resistance","volume":"70","author":"Majerczyk","year":"2016","journal-title":"Postepy Hig Med Dosw (Online)"},{"key":"2026012113073201900_ehf214567-bib-0037","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1161\/CIRCULATIONAHA.116.024503","article-title":"Retinol-binding protein-dependent cholesterol uptake regulates macrophage foam cell formation and promotes atherosclerosis","volume":"135","author":"Liu","year":"2017","journal-title":"Circulation"},{"key":"2026012113073201900_ehf214567-bib-0038","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.659977","article-title":"Biological functions of RBP4 and its relevance for human diseases","volume":"12","author":"Steinhoff","year":"2021","journal-title":"Front Physiol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/1\/179\/64508857\/eschf_11_1_179.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/1\/179\/64508857\/eschf_11_1_179.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:08:03Z","timestamp":1769018883000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/11\/1\/179\/8268224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,25]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,10,25]]},"published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14567","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2023,10,25]]},"assertion":[{"value":"2023-08-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}